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ABSTRACT 
Specific CD8 T-cell responses to human immunodeficiency virus type 1 (HIV-1) are 
induced in primary infection and make an important contribution to the control of early 
viral replication.  The importance of neutralizing antibodies in containing primary 
viremia is questioned because they usually arise much later.  Nevertheless anti-envelope  25 
antibodies develop simultaneously with, or even before, peak viremia.  We determined if 
such antibodies might control viremia by complement-mediated inactivation (C’MI).  In 
each of seven patients studied, antibodies capable of C’MI appeared at or shortly after the 
peak in viremia, concomitantly with detection of virus-specific T-cell responses.  The 
C’MI was effective on both autologous and heterologous HIV-1 isolates.  Activation of  30 
the classical pathway and direct viral lysis were at least partly responsible.  Since IgG-
antibodies triggered the C’MI, specific memory B-cells could also be induced by 
vaccination.  Thus consideration should be given to vaccination strategies that induce IgG 
antibodies capable of C’MI. 
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INTRODUCTION 
To design a successful vaccine against HIV it is important to determine which arm of the 
immune response is capable of recognizing and destroying invading virus before 
infection becomes systemic.  Studies of early infection can give clues as to the relevant 
immune response in controlling viral replication.  Primary HIV-1 infection (PHI) is  40 
characterized by an uncontrolled viremia, which subsequently settles on a lower steady 
level.  This viral load ‘set-point’ is a prognostic indicator for the subsequent rate of 
disease progression (12, 17, 22).  It has been long established that cytotoxic T 
lymphocyte (CTL) activity can be detected concurrent with the initial decrease in plasma 
viral RNA levels, suggesting that the control of plasma viremia is at least partly due to  45 
cell mediated immune responses (5, 13, 24).  In contrast, the role of humoral immunity 
and neutralizing antibodies (Nabs) has remained elusive (21).  Although Nabs can be 
detected as early as 4 weeks after onset of symptoms in some patients (2, 28), they are 
generally absent or weak until several months after infection (1, 13, 20, 25, 26, 36).  Anti-
envelope antibodies, however, are generally present from the time-point of initial  50 
containment of viremia (1, 15, 16).  In addition to direct interference with viral entry, 
antibodies  in vivo mediate opsonization, antibody dependent cellular cytotoxicity 
(ADCC) and complement activation (6, 7).  This led us to question whether early anti-
envelope antibodies have a role in viral inactivation, not detectable in traditional 
neutralization assays, by triggering complement activation.  55 
 
In this study of seven patients who initially presented with symptomatic primary 
infection, we show that immunoglobulin (Ig) G antibodies to the HIV-1 envelope present   4
at, or close to, peak viral load, can inactivate virus by direct viral lysis through activation 
of the classical complement pathway.  In all patients the development of such antibodies  60 
mirrored the early detection of HIV-1 specific T-cell activity.  These complement-
activating antibodies can inactivate both autologous and heterologous virus in the 
majority of the patients.  This suggests that it would be wise to incorporate envelope 
antigens capable of inducing such effector antibodies in potential vaccine candidates. 
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MATERIALS AND METHODS 
Cells and viruses.  Human glioma cells NP2, stably transfected with CD4 and CCR5, 
and 293T cells were grown in Dubelcco’s Modified Eagle Medium (DMEM; Invitrogen, 
Paisley, UK) with 5% Foetal Calf Serum (FCS; Invitrogen, Paisley, UK).  Chimeric  70 
viruses, and the molecular clone HIV-1YU2, were produced by transfecting 293T cells.  
HIV-1YU2 was also grown in phytohaemagglutinin (PHA) stimulated PBMC, obtained 
from blood donors.  The PBMC were cultured in RPMI-1640 (Invitrogen, Paisley, UK) 
supplemented with 10% FCS and 20 U/ml interleukin-2 (Roche, Lewes, UK). 
  75 
Patients.  Seven men who have sex with men (27-41 years old) presenting with PHI (5-
26 days following onset of symptoms, DFOSx), following sexual exposure, were 
enrolled.  Recent HIV-1 infection was diagnosed by the detection of HIV-1 genomes 
(PBMC proviral DNA or plasma RNA) in the presence or absence of an evolving HIV-1 
antibody profile, which subsequently became fully positive, or by a fully positive HIV-1  80 
antibody test within three months of a negative HIV-1 antibody test (MM4).  Blood   5
samples were obtained weekly for the first month, monthly for three months and then at 
3-monthly intervals.  At each visit the patients’ HIV-1 viral load (Chiron 3.0; Chiron, 
Emeryville, California, USA) was determined.  MM22 commenced antiretroviral therapy 
at day 26 post-symptoms; only serum samples collected prior to this date were analyzed.   85 
The study protocol was approved by The Camden and Islington Community Services 
Local Research Ethics Committee and written informed consent obtained from all 
subjects. 
 
Amplification of gp120 and generation of chimeric molecular clones.  Viral envelopes  90 
were amplified from proviral DNA from patient PBMC as described previously (1).   
Briefly, the gp120 was amplified using the primers 988L+ 5’-
GTAGCATTAGCGGCCGCAATAATAATAGCAATAG-3’, 943S+ 5’-CAA 
TAG(CT)AGCATTAGTAGTAG-3’, 609RE- 5’-
CCCATAGTGCTTCCGGCCGCTCCCAAG-3’ and 628L- 5’- 95 
TCATCTAGAGATTTATTACTCC-3’ for the first round.  For the nested polymerase 
chain reaction (PCR), primers 626L+ 5’-GTGGGTCACCGTCTATTATGGG-3’ and 
125Y- 5’-CACCACGCGTCTCTTTGCCTTGGTGGG-3’ were used, which contain 
BstEII and MluI sites (bold).  The PCR conditions were: 30 cycles of 92 ºC for 45 
seconds (s), 45 ºC for 45 s and 68 ºC for 210 s.  The amplified DNA-fragment was cloned  100 
into pGEM-T Easy (Promega, Southampton, UK) and transferred into pHxB2-MCS-∆-
env, by digestion with BstEII and MluI.  Plasmid pHxB2-MCS-∆-env  allows 
incorporation of heterologous gp120 sequences from amino acid 38 (seven amino acids 
after the signal peptide) to six amino acids prior to the gp120/gp41 junction (19).  The   6
resulting molecular clones encode replication competent viruses with gp41 derived from  105 
HIV-1HxB2. 
 
Virus titration.  Ten-fold serial dilutions of viral stocks were incubated on semi-
confluent NP2/CD4/CCR5 cells, seeded in 48-well plates, for 2 hours at 37 ºC.  The cells 
were then washed once and cultured for 72 hours.  Infection was detected by p24- 110 
immunostaining, as detailed elsewhere (1).  Briefly, fixed cells were incubated with 
mouse anti-HIV-1 p24 monoclonal antibodies (ADP 365 and 266, NIBSC, Potters Bar, 
UK; 1:40 dilution for 1 hour) followed by a goat anti-mouse Ig antibody conjugated to β-
galactosidase (Southern Biotechnology Associates, Birmingham, Alabama, USA; at 2.5 
µg/ml for 1 hour).  After incubation with X-Gal substrate at 37 ºC, infected cells appear  115 
blue and focus-forming units (FFU) are counted using light microscope. 
 
T-cell assays.  HIV-specific T-cell responses were assessed using recombinant vaccinia 
virus-based IFN-γ ELISPOT assays (14).  Responses were measured to a control 
recombinant vaccinia virus (vSC8) and vaccinia recombinants expressing HIV-1 gp160  120 
(vPE16), Gag (vAbT-141.5.1), Pol (vCF21), Nef (vTFnef2) or Tat (vTat) (all derived 
from clade B viruses).  Results are expressed as the mean (of duplicate or triplicate wells) 
number of protein-specific spot forming cells (SFCs) per 10
6 PBMCs, i.e. the mean 
number of cells producing IFN-γ in response to stimulation with the recombinant 
vaccinia virus expressing a given HIV protein minus the mean response observed to the  125 
control recombinant vaccinia virus. 
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Detection of anti-gp120 antibodies by enzyme-linked immunosorbent assay 
(ELISA).  For detection of anti-gp120 Abs in sera, HIV-1IIIB gp120 (NIBSC product No. 
EVA657, Potters Bar, UK) were bound to 96-well Maxisorb plates (Nalgene, NUNC  130 
International) which had been coated with antibody D7324 (10 µg/mL, over night) and 
pre-blocked with 1% milk powder (Marvel, 1 hour).  D7324 (Aalto Bio Reagents, 
Dublin, Ireland) is a polyclonal antibody that recognizes a conserved epitope in the C-
terminus of HIV-1.  Serial diluted patient sera (from 1:100) in 100 µL TMT/GS (4% 
Marvel, 10% goat serum and 0.05% Tween 20 in TBS) was added to duplicate wells with  135 
captured envelope and to duplicate wells containing no gp120 (blanks), for background 
subtraction.  Bound antibodies were subsequently detected with an alkaline phosphatase 
(AP) conjugated goat-anti-human Ig antibody (Harlan SeraLab, UK; diluted 1:2000 in 
TMT/GS) followed by a substrate solution (Lumi-Phos Plus, Aureon BioSystems GmBH, 
Austria).  Relative light units were measured at 405 nm.  Cut off for a positive reaction  140 
was set to 100 light units above background.  At this cut of value none of more than ten 
HIV-seronegative control sera tested scored positive. 
 
Complement.  Complement was prepared from clotted blood from HIV-seronegative 
individuals and stored in aliquots at –80 ºC.  Complement was inactivated by incubating  145 
the serum at 56 ºC for 2 hours.  Guinea pig complement was reconstituted in PBS 
(Sigma, Poole, UK).  C3 deficient serum was reconstituted with recombinant human C3 
(Sigma, Poole, UK) to physiological concentration (1.2 mg/ml).   8
 
Neutralization and C’MI assays.  Serial diluted heat-inactivated patient sera were  150 
incubated with 100 FFU of HIV-1 in a volume of 100 µL, for 1 hour at 37 ºC.  To detect 
C’MI, a source of complement (HIV-seronegative human serum) was also included and 
added at a final concentration of 10% (v/v).  As a negative control, parallel assays were 
run with heat-inactivated complement.  Following the incubation the serum-antibody-
virus cocktail was added to NP2/CD4/CCR5 cells, seeded in 48-well plates.  After 2  155 
hours incubation at 37 ºC, the cells were washed once and then cultured for 72 hours.  
Infection was measured by p24-immunostaining, as described above (see virus titration).  
The percentage reduction of infection in the presence of antibody (i.e. patient serum) and 
complement was calculated using the following formula: 100 x [1-(average FFU in the 
presence of patient serum and complement / average FFU in the presence of complement  160 
only)].  The percentage neutralization was calculated using the same formula, but with 
the virus assayed in the presence of heat-inactivated complement.  Each patient-serum 
was assayed in triplicate, at least twice.  Unless otherwise stated, presented data refers to 
patient-serum activity at a 1:10 dilution, with error bars showing the standard deviation 
between repeated independent experiments.  For determination of serum neutralization  165 
end-point titres, FFU obtained in the presence of serial dilutions of patient serum was 
compared with FFU obtained in the presence of HIV-1 seronegative serum at a 1:10 
dilution (both serum sources heat-inactivated).  The threshold for a positive neutralization 
reaction was set to 90%, as reductions below this level are intrinsically variable between 
experiments (1).  170 
   9
Affinity purification of IgG.  IgG was isolated from plasma using the MAbTrap kit 
(Amersham Biosciences, Little Chalfont, UK). 
 
Detection of viral lysis.  Viral lysis by complement and antibody was assessed by  175 
quantification of reverse transcriptase (RT) activity in virus suspensions following 
incubation at 37 °C for 1 hour.  HIV-1YU2 (~10,000 FFU derived from 293T cells or 
1,000 FFU from PBMC) was incubated with heat-inactivated patient sera (or 
seronegative sera) in the presence of 10% (v/v) complement in a 100 µl volume.  RT 
activity was measured using the Lenti-RT Activity Assay (Cavidi Tech AB, Uppsala,  180 
Sweden).  The amount of free RT in the samples is measured in a two-step procedure.  
Immobilized polyA template (in a microtiter plate) is reverse transcribed by free RT in 
the samples using bromo-deoxyuridine triphospate (BrdUTP) as nucleotide source.   
Incorporated BrdUMP is quantified in a colorimetric assay using an anti-BrdU antibody 
conjugated to alkaline phosphatase.  Specifically, 50 µl of virus sample diluted 1:5 in the  185 
detergent free sample-dilution buffer was applied to duplicate wells for 3 hours.  The 
plates was then washed once with detergent-free wash-buffer and subsequently processed 
following the supplied protocol for RT quantification.  RT release is expressed as 
percentage increase in RT activity in virus suspensions incubated with complement in the 
presence of patient sera.  190 
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RESULTS 
Late development of neutralizing antibodies.  For this study we enrolled seven men 
between 27-41 years of age who initially presented with symptoms characteristic of PHI.   195 
To study the development of antibody-mediated neutralization, autologous envelopes 
(SU, gp120) were cloned into a HIV-1HXB2 based vector from patient PBMC at the 
earliest time-point available (between day 6 and 28 post onset of symptoms of PHI).  We 
have previously shown that viral envelopes directly cloned in this way are representative 
of a homogeneous population of replicating viruses in vivo (1).  The time to development  200 
of autologous Nabs ranged from 81 to 466 days post onset of symptomatic PHI (Table 1).  
Two patients, MM19 and MM28, developed intermediate activity (75-85%) by day 287 
and day 405, respectively, but did not attain full neutralizing activity (≥90% reduction in 
virus infection) throughout the study (last sampled at day 701 and 503, respectively).  
This range of times to development of autologous virus neutralization is similar to that  205 
reported previously (1, 28, 36).  All patients initiated a decline in viremia within the first 
month of symptomatic PHI, clearly preceding their development of Nabs (supplemental 
online material). 
 
HIV-specific T-cell activity is detected from the earliest time-point.  Unlike Nab,  210 
HIV-specific CTL responses can be detected prior to the peak in acute-phase viral 
replication, with strong virus-specific CD8 T-cell responses being temporally associated 
with the decline in primary viremia (5, 13, 24, 37).  We confirmed that HIV-specific T-
cell responses could be detected in this patient cohort during the acute phase of infection 
by using recombinant vaccinia virus-based IFN-γ ELISPOT assays to assess T-cell  215   11
responses to five HIV proteins: gp160, Gag, Pol, Nef and Tat at the earliest time-points 
for which PBMC samples were available.  In five of the seven patients (MM8, MM19, 
MM22, MM23 and MM28), T-cell responses were assessed within two weeks of onset of 
symptoms of PHI, at time-points when the plasma viral load was in excess of 3,000,000 
RNA copies/ml – i.e. at or close to the peak in acute viral replication; and in a sixth  220 
patient (MM27) the response was tested at a slightly later time-point, when the viral load 
was in decline.  There were no appropriate PBMC samples available for testing from the 
seventh patient (MM4).  In all six patients tested, T-cell responses were detected to at 
least two of the HIV proteins used at these acute (or very early) time-points (Table 2).  
Limited sample availability precluded confirmation of the phenotype of the responding T  225 
cells, but both we and others (12) have previously shown that the HIV-specific responses 
detected in these assays are predominantly mediated by CD8
+ T cells. 
 
Antibody dependent complement mediated inactivation of virus is also detectable at 
acute infection time-points.  In contrast to the delayed development of Nabs, anti- 230 
envelope antibodies were detectable in the first serum samples taken 6-28 days after 
onset of symptoms, as expected from our previous study (1).  We tested whether the 
presence of complement could augment antiviral activity of early sera and thus if the 
early anti-envelope antibodies might contribute to the decline in viremia during primary 
infection.  HIV-seronegative human serum was used as a source of complement and heat- 235 
inactivated aliquots served as negative controls.  Inclusion of complement had a marked 
effect on the potency and time to development of serum mediated anti-viral activity (Fig.   12
1a).  All activity was ablated if the source of complement was heat-inactivated, with 
neutralization titers remaining the same as with patient serum alone. 
  240 
The potency of the C’MI response varied from patient to patient and the profiles fell into 
three distinct patterns (Fig. 1a).  Acute sera from MM4, MM8 and MM19 had weak and 
varied neutralizing activity in the absence of complement but demonstrated potent viral 
inactivation (90-100%) in its presence, even at the first sampling time-points.  Thus 
MM4, MM8 and MM19 achieved significant complement dependent ‘neutralization’ of  245 
viral infection by days 17, 12 and 13 respectively.  MM23 and MM28 exhibited a 
different profile; their early sera lacked any detectable neutralizing activity (until day 204 
and >503, respectively) but again substantial C’MI activity was evident from the earliest 
sample at day 9 and 6, respectively.  The third pattern was observed for MM27 where 
weak neutralizing activity was steadily augmented over time by complement, from the  250 
first sample at day 28.  No C’MI activity was observed with sera from MM22, but we 
could only analyze sera between days 14-25 since this patient commenced antiretroviral 
therapy at day 26. 
 
Typical titration curves of C’MI activity at early and chronic infection time-points is  255 
shown in Fig. 1b, illustrating that the C’MI activity is detectable at higher serum dilutions 
(>1:10) than that used in Fig. 1a.  At later time-points when ‘conventional’ neutralizing 
activity developed the C’MI effect augmented the neutralizing activity.  IC90 end-point 
titers were generally enhanced two- to four-fold, irrespective of the C’MI potency at early 
time-points (Fig. 1b).  260   13
Table 3 summarizes the first time-point at which anti-envelope Abs, Nab, C’MI and T-
cell activity was detected for each patient.  The status of the patients’ virus loads at these 
time-points is also indicated and shows that the majority had detectable C’MI in the acute 
viremic phase, characterized by high viral loads (>3,000,000 RNA copies/ml).   
Autologous C’MI and T-cell activity developed at least 2 months earlier than Nab  265 
activity, and typically more than 6 months earlier (range 69– >503 days).  Apart from 
MM22, all patients developed antibodies capable of C’MI of autologous virus by the first 
sampling point.  The most striking difference was seen in patient MM28 whose date for 
first detectable anti-HIV antibody activity was shifted from more than 503 days to day 6.  
Thus we have shown that antibody dependent C’MI of HIV-1, in contrast to Nabs, arises  270 
during acute infection when containment of viral replication is initiated.  These results 
implicate a role for humoral immunity in control of viremia in primary HIV-1 infection. 
 
The C’MI by patient sera is broad and inactivates heterologous HIV-1 isolates.  The 
viruses tested so far were derived from molecular clones encoding autologous, patient- 275 
specific envelope.  Apart from two patients (MM4 and MM8), who showed weak 
heterologous neutralizing activity (50%) from 200 days post onset of symptomatic PHI, 
no significant (>90%) heterologous neutralization was detected in any patient within the 
first year (Fig. 2a).  We tested how broad the C’MI activity is using envelopes from an 
unrelated seroconverter (by testing responses to MM4’s virus, HIV-14.1.33, in the other  280 
seroconverters) and the molecular clone HIV-1YU2.  In striking contrast to heterologous 
neutralization, apart from patient MM27, all patients developed heterologous C’MI 
activity in the earliest sample tested between 9 and 28 days post onset of symptomatic   14
PHI (Fig. 2a).  In all cases the potency of C’MI reached levels similar to that of 
autologous virus inactivation.  A typical profile can be seen for patient MM19, with at  285 
least 90% inactivation of HIV-1YU2 concomitant with autologous virus inactivation and 
maintained antiviral activity throughout the study period (Fig. 1a and 2a).  The HIV-1YU2 
virus was often more sensitive to C’MI than HIV-14.1.33 and in some cases inactivation of 
HIV-1YU2 was stronger than that of the autologous virus.  For example, MM22 scored 
less than 40% inactivation of his own virus yet reached almost 100% inactivation of HIV- 290 
1YU2.  The lack of C’MI of heterologous viruses by serum from MM27 maybe linked to 
the weak autologous C’MI activity in this patient (Fig. 1a). 
 
Previous reports have suggested that PBMC cultured HIV-1 is relatively resistant to 
C’MI (30, 32).  In agreement with these studies we observed that PBMC-derived HIV- 295 
1YU2 virus is less susceptible to C’MI compared to 293T-derived virus (Fig. 2b). 
 
Characterization of the antiviral activity.  As shown above the antiviral effect is most 
likely to be mediated by complement because it is lost after heat-inactivation.  We sought 
to determine that this antiviral response is indeed mediated by complement, rather than  300 
some other unknown heat-labile component, using purified guinea pig complement.  No 
neutralization of autologous virus with serum from MM8 day 49 was observed in the 
absence of complement (Fig. 3a).  Substitution of human serum as a source of 
complement with purified guinea pig complement resulted in inactivation profiles similar 
to C’MI with human serum as source (Fig. 3a).  Thus, a purified source of complement  305   15
proteins can substitute for human serum in virus inactivation by antibodies early in 
infection. 
 
The complement cascade in vivo can be activated by an antibody dependent (classical), 
an antibody independent (alternative) or a lectin pathway (4).  In order to determine the  310 
pathway involved in the observed antiviral effect, we substituted the complement source 
with sera obtained from C1q and C3 deficient individuals.  C1q deficiency results in an 
inability to activate the classical pathway while C3 deficient individuals fail to execute 
the final common pathway.  We tested the first serum sample from two patients, MM8 
and MM28.  In the presence of complement we observed almost 70% inactivation of  315 
input virus, which was completely ablated when the source of complement was heat-
inactivated (Fig. 3b).  When the source of complement was derived from C1q or C3 
deficient individuals, the antiviral effect of both patients’ sera was reduced to less than 
20% (C1q) and 10% (C3), respectively (Fig. 3b).  For C3 deficient serum, the antiviral 
effect was recovered by addition of recombinant C3, demonstrating the specificity of the  320 
antiviral effect (Fig. 3b).  The ablation of the antiviral effect in the absence of C1q 
confirms that the classical complement pathway is largely responsible for the antiviral 
effects observed. 
 
Following infection with HIV-1, IgG1 and IgG3 are the predominant subtypes induced in  325 
plasma and cervicovaginal, seminal and rectal secretions (27), and these are potent 
activators of the complement pathway (6).  We wished to establish if the early C’MI 
activity observed is mediated by IgG antibodies.  This is of interest since vaccine-induced   16
immunological memory is likely to be mediated through IgG antibodies.  Affinity 
purified IgG from day 13 serum from patient MM19 was tested for C’MI activity and  330 
resulted in 50% reduction of input virus (Fig. 3c).  This is less than the 90% reduction 
observed with unfractionated sera (Fig. 1a), possible due to dilution of IgG or the 
removal of IgM during the purification process.  As expected, since whole serum was 
non-neutralizing, purified IgG either alone (data not shown) or in the presence of heat-
inactivated complement had no effect on viral infectivity (Fig. 3c).  The C’MI was also  335 
mediated largely through IgG antibodies from the same patient in the chronic phase (day 
701) (Fig. 3c). 
 
We sought to define the mechanism of this IgG mediated antiviral effect.  If direct lysis 
of virus plays a role, incubation of virus with antibody and complement would enhance  340 
the release of virion components normally contained within the viral envelope, for 
example RT (31).  We measured the levels of RT activity in viral supernatants after 
treatment with serum and complement and compared them to virus supernatants in the 
presence of complement alone.  Virus treated with both anti- HIV-1 serum and 
complement resulted in approximately 100% more RT release compared to treatment  345 
with non-immune serum and complement (Fig. 3d).  The level of viral lysis was similar 
in 293T and PBMC produced viruses.  This indicates that viral lysis is at least partially 
responsible for C’MI. 
 
  350 
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DISCUSSION 
Here we demonstrate that antibodies to the HIV-1 envelope, like CTLs, may control the 
acute viremia in HIV-1 infection.  We detected IgG antibody-mediated complement 
inactivation of either autologous and/or heterologous HIV-1 strains in all patients as early  355 
as 6-28 days post onset of symptomatic PHI.  In contrast, autologous Nabs generally 
developed more than 200 days after symptomatic PHI and heterologous neutralization 
was even later, if at all detectable.  We also demonstrate that activation of the classical 
complement pathway is the major effector pathway.  When serum from uninfected C1q 
or C3 deficient individuals was used as a complement source no anti-viral activity was  360 
observed.  Direct lysis of virions is at least in part the mechanism by which virus is 
inactivated, although coating of virons by complement components may also contribute 
to the viral inactivation (32, 35).  Other studies have implicated antibodies in ADCC 
mediated antiviral activity early in infection, preceding the development of neutralizing 
activity (9, 10).  Although we have not formally demonstrated it here, it is likely that  365 
Nabs serve the ‘dual role’ of both neutralizing and complement-activating antiviral 
activity.  Since IgG antibodies mediated the C’MI we suggest that it should be possible to 
induce an effective C’MI memory B-cell response with candidate vaccines.  It may also 
be advisable to ensure that complement-activating antibody-subtypes are induced through 
the choice of suitable adjuvants (8, 23).  370 
 
The susceptibility of a virus to C’MI has been linked to the level of complement 
regulatory proteins such as CD55, CD46 and CD59 expressed on the producer cells and 
incorporated into virions (18, 29, 30, 32).  The viruses used in this study were produced   18
in 293T cells, which express all three regulatory proteins (data not shown).  In agreement  375 
with others (30, 32), we observed that PBMC-derived virus is less susceptible to C’MI 
compared to 293T-derived virus.  Indeed, the in vivo interactions between HIV-1 and 
complement are controversial and may in certain circumstances enhance infection, for 
example infection of dendritic cells (3, 33).  Nonetheless, Spear and colleagues have 
shown that uncultured HIV-1 purified directly from patient plasma is highly susceptible  380 
to C’MI (34), supporting the in vivo relevance of our findings.  Furthermore, data from 
Gauduin et al. support a role for complement in passive antibody-mediated protection 
against HIV-1 infection in a (human-PBL-SCID) mouse model (11). 
 
In conclusion we have demonstrated a previously overlooked potential role for antibodies  385 
in the control of viremia in acute HIV-1 infection.  We recommend that envelope 
antigens capable of inducing both neutralizing and ‘C’MI-neutralizing’ antibodies should 
be included in addition to CTL inducing antigens in candidate HIV-1 vaccines.  Further 
studies will be needed to determine whether specific epitopes of the HIV-1 envelope will 
need to be targeted.  390 
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FIGURE LEGENDS 
 
FIG. 1.  Development of C’MI and neutralization activity in HIV-1 infected patients.  (a) 
The percentage reduction in infection of 100 FFU of autologous virus in the presence of  535 
sequential patient sera (at a dilution of 1:10), assayed in the presence (closed data points) 
or absence (i.e. neutralization, open data points) of complement is shown.  HIV-1 
seronegative sera served as complement source (added at a final concentration of 10% 
(v/v)), and heat-inactivated aliquots as negative controls.  The error bars refer to the 
standard deviation between two or three independent experiments.  (b) Typical C’MI and  540 
neutralization with increasing dilution of patient-serum from an early and a later infection 
time-point.  The error bars refer to the standard deviation between two independent 
experiments. 
 
FIG. 2.  C’MI and neutralization of heterologous viruses.  For experimental details see  545 
Fig. 1.  As before closed symbols represents C’MI and open symbols neutralization.  The 
error bars refer to the standard deviation between two or three independent experiments.  
(a) C’MI and neutralization of heterologous viruses produced in 293T cells.  Data for 
HIV-1YU2 is indicated with squares, and HIV-14.1.33 data with triangles.  (b) Data for HIV-
1YU2 passaged through PBMC.  550 
 
FIG. 3.  Characterization of the anti-HIV activity in patient sera.  (a) Guinea pig 
complement can substitute for human complement in C’MI assays using day 49 serum 
from patient MM8 (closed squares).  C’MI activity is lost following heat-inactivation   27
(open squares).  (b) Serum form C1q or C3 deficient individuals cannot mediate the  555 
antiviral activity observed with normal human serum as complement source.   
Reconstitution of C3 restores the antiviral activity.  (c) Affinity purified IgG antibodies 
mediate the complement-dependent virus inactivation.  Black fill represents activity in 
the presence of complement and white is in the presence of heat-inactivated complement.  
(d) Release of RT from virions was measured by Lenti-RT Activity Assay (Cavidi Tech  560 
AB, Sweden), under non-lysing detergent-free conditions, after treatment with serum and 
complement.  HIV-1YU2  derived from either 293T cells or PBMC was assayed for 
susceptibility to complement mediated lysis.  Non-immune serum had no effect on RT 
release compared to complement alone (open squares).  Immune serum, however, 
resulted in 100% increase in RT activity (closed symbols).  Data presented show activity  565 
of MM28 sera, from day 20 for the 293T produced HIV-1YU2 and from day 34 (squares) 
and day 93 (diamonds) for PBMC produced HIV-1YU2.     28
TABLE 1.  Neutralising activity of sequential autologous sera 
 
a Neutralization titers are expressed as the reciprocal dilution of serum required to reduce  570 
infectivity ≥90% (IC90) compaired to HIV-1 seronegative sera (at a dilution of 1:10), as 
measured by immunostaining of infected NP2/CD4/CCR5 cells. 
b The sequential sera were tested against chimeric viruses with patient-derived viral 
envelopes. 
c Time-point from which patients’ viral envelopes were cloned, numbers refering to  575 
DFOSx. 
d The neutralization profiles for these patients have been described previously (14). 
Symbols: -, no samples obtained; <10, 90% neutralization was not observed at the lowest 
(1:10) serum dilution tested; nd, not determined, as MM22 commenced antiretroviral 
therapy 26 days after onset of symptoms.  580 
     
    IC90 at days from onset of symptomatic primary HIV-1 infection
a 
     
     
Patient   Virus
b   Isolation 
day
c   <14  15-
28 
30-
40 
49-
66 
80-
110 
185-
206 
269-
300 
310-
340 
350-
410 
456-
466 
490-
520 
570-
631  >690 
                        
                        
MM4
d  4.1.33  17  -  <10  <10  <10  <10  20 10 20 20  -  20 20 40 
                      
MM8
d  8.2.50 12 <10  <10  -  <10  10  20 - 20 -  -  - 20  40 
  8.2.51 12 <10  <10  -  <10  10  20 - 80 -  -  - 80  80 
                         
MM19  19.1.A 13 <10  <10  <10  <10  <10 <10  <10  -  <10 <10 <10  -  <10 
                        
MM22  22.2.D 14 <10  <10  nd  nd  nd  nd  nd nd nd nd  nd nd nd 
                      
MM23  23.2.E  15  <10  <10  <10  <10  - 80  - 160 -  - 320  160 - 
                        
MM27 27.1.J  28  -  <10 <10 <10  <10  <10  <10  -  - 10 - 20 - 
                        
MM28 28.1.5  6  <10 <10 <10 <10  <10  <10  - -  <10 - <10 -  - 
  28.1.6 6  <10  <10  <10  <10  <10  <10  - -  <10 - <10 -  - 
                          29
TABLE 2.  Virus-specific T-cell activity during the acute-phase primary viremic burst 
 
a T-cell responses to five HIV proteins (gp160, Gag. Pol, Nef and Tat) were assessed at 
the indicated time-points (days from onset of symptoms) during acute (MM8, 19, 22, 23, 
and 28) or very early (MM27) infection using recombinant vaccinia virus-based IFN-γ  585 
ELISPOT assays.  The values shown indicate the magnitude of the response observed to 
each HIV protein, expressed as the mean number of protein-specific IFN-γ spot forming 
cells per 10
6 PBMCs (+ 1 standard deviation).  
    
   T  cell  response
a 
        
        
Patient Time-point 
(DFOSx) 
gp160 Gag  Pol  Nef  Tat 
        
        
MM8  12   473 + 7         0   528 + 130         0         0 
           
MM19  13   45 + 20     92 + 20     47 + 27      5 + 20         0 
           
MM22 14 78  + 20     35 + 55   247 + 21         0         0 
           
MM23 9  265  + 221   345 + 154     87 + 42     38 + 59     85 + 74 
           
MM27  28    4 + 13     17 + 21     28 + 5         0     28 + 26 
           
MM28  6     73 + 0     58 + 7   105 + 32     55 + 32   858 + 148 
          30
TABLE 3.  First detection time-points for T-cell and antibody mediated antiviral activity 
following infection  590 
 
a  All patients had detectable levels of anti-HIV Abs from the first study sample in 
diagnostic tests (Murex HIV-1.2.0, Abbott, Germany; Wellcozyme HIV Recombinant, 
Abbott, Germany; Serodia HIV-1/2, Fujirebio INC, Japan and VIDAS HIV Duo, 
bioMérieux, France).  595 
b The titer of anti-gp120 Abs in patient sera was determined by an in-house ELISA, as 
described in Material and Methods, the lowest serum dilution tested was 1:100. 
c HIV-specific T-cell responses were detected in recombinant vaccinia virus-based IFN-γ 
ELISPOT assays (Table 2). 
d  The antibody dependent complement mediated virus inactivation (C’MI) was  600 
intermediate (approximately 50% inactivation of input virus) in early serum from patients 
              
Patient Time-
point 
(DFOSx) 
Viral load 
(RNA 
copies/ml) 
Anti-
HIV 
Abs
a 
Anti-gp120 Abs 
(reciprocal  
end-point titer)
b 
T-cell 
activity
c 
C’MI
d Nab
e 
             
             
MM4 17 160,000  +  100  nd  +  - 
  206 30,200   12,800     + 
             
MM8   12  5,927,000  +  <100  +  +  - 
 81  41,900    3,200      + 
             
MM19 13 5,678,900  +  <100  +  +  - 
  519 371,700   12,800      - 
             
MM22   14  8,311,000  +  100  +  nd  nd 
             
MM23   9  11,105,300  +  <100  +  +  - 
  204 117,600   51,200      + 
             
MM27   28  353,200  +  800  +  +  - 
  466 10,600   12,800     + 
             
MM28   6  4,337,100  +  100  +  +  - 
  503 38,600   102,400     - 
               31
MM23, MM27 and MM28, and strong (approximately 90% inactivation of input virus) in 
early serum from patients MM4, MM8 and MM19. 
e Neutralization defined as ≥90% reduction of infection of input virus (Table 1). 
Symbols: +, detectable response; -, undetectable responses; nd, not determined, as no  605 
(suitable) samples were available for analysis.   1
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